What is the most appropriate diagnosis and treatment for a 23-year-old female with acute severe psychosis (auditory and visual hallucinations, delusions, thought disorganization), depressive, anxiety, and manic symptoms, family history of schizophrenia and bipolar disorder, recent THC and alcohol use, prior suicide attempt and homicidal thoughts, currently on sertraline (Zoloft) and aripiprazole (Abilify), with medication noncompliance and housing instability?

Diagnosis and Treatment Recommendation

This patient requires immediate hospitalization for acute psychotic disorder, likely first-episode psychosis with differential of schizophrenia versus bipolar disorder with psychotic features, and her current regimen of sertraline and aripiprazole is inadequate and potentially harmful—discontinue sertraline immediately, optimize aripiprazole dosing to therapeutic levels (10-30 mg daily), and prepare for potential clozapine trial if symptoms persist after 4 weeks of adequate antipsychotic monotherapy. 12

Immediate Safety and Diagnostic Priorities

Hospitalization is mandatory given:

• Active homicidal ideation toward family member
• Prior suicide attempt with ongoing risk
• Severe psychosis with impaired reality testing and poor insight
• Housing instability and medication noncompliance
• Substance use complicating clinical picture

The diagnostic workup must rule out secondary causes before confirming primary psychotic disorder 3:

• Urine toxicology (THC and alcohol use documented—though severity of symptoms suggests primary disorder)
• Complete metabolic panel, CBC, thyroid function, B12, folate, calcium, parathyroid hormone
• HIV and syphilis testing
• Head imaging if any focal neurological signs or recent trauma
• Collateral history from family regarding onset, duration, and progression of symptoms

Diagnostic Formulation

Most likely diagnosis: First-episode psychosis, provisional schizophrenia or schizoaffective disorder given:

• Prominent positive symptoms (auditory/visual hallucinations, delusions, thought disorganization)
• Negative symptoms implied by poor insight
• Affective symptoms (depression, anxiety, possible mania)
• Strong family history of schizophrenia and bipolar disorder
• Age 23 (typical onset window)

The presence of both psychotic and mood symptoms with family history of both schizophrenia and bipolar disorder suggests schizoaffective disorder as a strong possibility 4. However, definitive diagnosis requires observing whether psychotic symptoms persist during euthymic periods.

Substance-induced psychosis is less likely because the severity, breadth of symptoms, family history, and documented behavioral abnormalities exceed what THC/alcohol typically produce, though substances may be exacerbating factors 3.

Critical Medication Error: Current Regimen

The combination of sertraline (Zoloft) with aripiprazole is problematic:

• Sertraline can worsen psychosis and may be contributing to symptom severity
• Antidepressants in acute psychosis without mood stabilization can destabilize patients
• There is no indication for antidepressant monotherapy in first-episode psychosis 12

Treatment Algorithm

Phase 1: Acute Stabilization (Weeks 0-4)

Discontinue sertraline immediately and optimize antipsychotic monotherapy:

1. Aripiprazole optimization 56:

   • Current dose unknown—titrate to 10-15 mg daily initially, can increase to 30 mg daily if needed
   • Aripiprazole is FDA-approved for schizophrenia and bipolar disorder 5
   • As a D2 partial agonist, it has favorable metabolic profile compared to olanzapine
   • Monitor for 4 weeks at therapeutic dose with confirmed adherence 1

2. Address medication adherence immediately:

   • Given documented noncompliance, strongly consider long-acting injectable (LAI) aripiprazole once stabilized 27
   • LAI formulations reduce relapse risk and improve outcomes in patients with adherence issues
   • Can transition to aripiprazole LAI (400 mg monthly) after oral stabilization

3. Manage acute agitation/insomnia:

   • Short-term benzodiazepines for severe agitation (lorazepam 1-2 mg PRN)
   • Consider low-dose quetiapine or trazodone for insomnia if needed

Phase 2: If Inadequate Response at 4 Weeks

If significant positive symptoms persist after 4 weeks at therapeutic aripiprazole dose with good adherence 1:

1. Switch to alternative antipsychotic with different pharmacodynamic profile:

   • Since first-line was D2 partial agonist (aripiprazole), switch to:
     • Risperidone 2-6 mg daily, OR
     • Olanzapine 10-20 mg daily with concurrent metformin 500-1000 mg daily (to prevent metabolic effects), OR
     • Paliperidone 6-9 mg daily

2. Cross-titrate gradually based on half-lives and receptor profiles 1

3. Monitor for another 4 weeks at therapeutic dose with confirmed adherence

Phase 3: Treatment-Resistant Psychosis

If positive symptoms remain significant after second antipsychotic trial (8 weeks total) 12:

1. Reassess diagnosis and rule out:

   • Ongoing substance use
   • Medical/organic causes
   • Medication adherence issues

2. Initiate clozapine trial (1B recommendation) 12:

   • Clozapine is indicated for treatment-resistant schizophrenia
   • Also indicated if suicide risk remains substantial (highly relevant given prior attempt) 2
   • Start metformin 500 mg BID concurrently to prevent weight gain 1
   • Titrate clozapine to achieve plasma level ≥350 ng/mL
   • If inadequate response at 12 weeks, increase to target 350-550 ng/mL 1

Addressing Mood Symptoms

Do not add antidepressants during acute psychotic phase. Once psychosis is controlled:

• If depressive symptoms persist after psychosis resolves, aripiprazole has evidence as augmentation for depression 8
• If bipolar disorder confirmed, add mood stabilizer (lithium or valproate) rather than antidepressant
• Reassess mood symptoms only after psychosis stabilizes to determine if they are primary or secondary

Psychosocial Interventions (Concurrent with Pharmacotherapy)

Coordinate specialty care program for first-episode psychosis (1B recommendation) 2:

• Cognitive-behavioral therapy for psychosis (CBTp)
• Psychoeducation for patient and family
• Family interventions given family contact
• Assertive community treatment (ACT) given housing instability, poor engagement history, and high relapse risk 2
• Supported employment services when stabilized
• Address substance use with integrated dual diagnosis treatment

Monitoring and Follow-up

Weekly monitoring initially for:

• Psychotic symptom severity (PANSS or BPRS)
• Suicidal/homicidal ideation
• Medication adherence
• Side effects (weight, metabolic parameters, extrapyramidal symptoms)
• Substance use

Metabolic monitoring 5:

• Baseline: weight, BMI, waist circumference, fasting glucose, lipid panel
• Weight at every visit initially
• Metabolic panel at 12 weeks, then quarterly

Critical Pitfalls to Avoid

1. Do not continue antidepressant monotherapy in acute psychosis—can worsen symptoms
2. Do not delay clozapine if two adequate antipsychotic trials fail—suicide risk is high in this patient 2
3. Do not assume substance-induced psychosis given family history and symptom severity—treat as primary disorder
4. Do not discharge without addressing adherence—consider LAI formulation given documented noncompliance
5. Do not ignore housing instability—coordinate with social work for stable housing as part of discharge planning
6. Do not treat mood symptoms with antidepressants until psychosis controlled and diagnosis clarified

Prognosis Factors

Favorable: Young age, acute onset, family support available, willingness to engage (if achieved)

Unfavorable: Medication noncompliance, substance use, housing instability, prior suicide attempt, homicidal ideation, limited social supports

The key to improving this patient's outcome is ensuring medication adherence through LAI formulation and comprehensive psychosocial support through coordinated specialty care. 29